TABLE 5.
Number needed to prevent one death 10 years after the start of screening, according to HCC annual incidence and surveillance modality
| Annual HCC incidence | 6‐M US vs. no surveillance | 3‐M US vs. 6‐M US | 12‐M MRI vs. 6‐M US | 6‐M MRI vs. 6‐M US |
|---|---|---|---|---|
| HCC‐related mortality | ||||
| 0.2% | 356 | 1639 | 3846 | 1333 |
| 0.4% | 177 | 813 | 1923 | 667 |
| 1.5% | 49 | 224 | 538 | 184 |
| Overall mortality | ||||
| 0.2% | 535 | 2777 | 7692 | 2632 |
| 0.4% | 267 | 1388 | 3703 | 1299 |
| 1.5% | 74 | 341 | 1020 | 356 |
Note: Baseline case scenario relies on a tumor doubling time of 90 days.
Abbreviations: HCC, hepatocellular carcinoma; M, month; MRI, magnetic resonance imaging; US, ultrasound.